The monoaminergic tripartite synapse: A putative target for currently available antidepressant drugs

Current Drug Targets

Volumn 14, Issue 11, 2013, Pages 1277-1294

  Quesseveur, Gaël ^a   Gardier, Alain M ^a   Guiard, Bruno P ^a  

^a University of Paris XI   (France)

Author keywords

Antidepressants; Astrocytes; Depression; Gliotransmitters; Neurotrophic factors; Tripartite synapse

Indexed keywords

1 [2 (BENZHYDRYLOXY) ETHYL] 4 (3 PHENYLPROPYL) PIPERAZINE; 1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; ADENOSINE TRIPHOSPHATE; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; AMITIFADINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; APOMORPHINE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP; DESIPRAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; FIBROBLAST GROWTH FACTOR; FLUOXETINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; NISOXETINE; NORADRENALIN TRANSPORTER; PAROXETINE; ROPINIROLE; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ASTROCYTE; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL SURVIVAL; DEPRESSION; DRUG RESPONSE; ELECTROENCEPHALOGRAM; HIPPOCAMPUS; HUMAN; MICROARRAY ANALYSIS; MONOAMINERGIC SYSTEM; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROTRANSMISSION; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TRIPARTITE SYNAPSE;

ADULT; ANIMALS; ANTIDEPRESSIVE AGENTS; ASTROCYTES; BIOGENIC MONOAMINES; DEPRESSIVE DISORDER, MAJOR; HIPPOCAMPUS; HUMANS; MOLECULAR TARGETED THERAPY; NERVE GROWTH FACTORS; RECEPTORS, BIOGENIC AMINE; RECEPTORS, NEUROTRANSMITTER; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 84887941822     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113149990209     Document Type: Review

References (267)

1. Blier P. Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry 2001;62 Suppl 15:12-7.
2. El Mansari M, Guiard BP, Chernoloz O, Ghanbari R, Katz N, Blier P. Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther 2010; 16(3): e1-17.
3. Rajkowska G, Stockmeier CA. Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets 2013; 14(11): 00-00.
4. Banasr M, Chowdhury GM, Terwilliger R, et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 2010; 15(5): 501-11.
5. Czeh B, Simon M, Schmelting B, Hiemke C, Fuchs E. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology 2006; 31(8): 1616-26.
6. Gosselin RD, Gibney S, O'Malley D, Dinan TG, Cryan JF. Region specific decrease in glial fibrillary acidic protein immunoreactivity in the brain of a rat model of depression. Neuroscience 2009; 159(2): 915-25.
7. Banasr M, Duman RS. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry 2008; 64(10): 863-70.
8. Katz DM, Kimelberg HK. Kinetics and autoradiography of high affinity uptake of serotonin by primary astrocyte cultures. J Neurosci 1985; 5(7): 1901-8.
9. Inazu M, Takeda H, Ikoshi H, Sugisawa M, Uchida Y, Matsumiya T. Pharmacological characterization and visualization of the glial serotonin transporter. Neurochem Int 2001; 39(1): 39-49.
10. Mazzio E, Becker A, Soliman KF. Inflammation and inducible nitric oxide synthase have no effect on monoamine oxidase activity in glioma cells. Biochem Pharmacol 2003; 65(10): 1719-27.
11. Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 2008; 13(10): 855-70.
12. Hirst WD, Price GW, Rattray M, Wilkin GP. Identification of 5-hydroxytryptamine receptors positively coupled to adenylyl cyclase in rat cultured astrocytes. Br J Pharmacol 1997; 120(3): 509-15.
13. Porter JT, McCarthy KD. Astrocytic neurotransmitter receptors in situ and in vivo. Prog Neurobiol 1997; 51(4): 439-55.
14. Verkhratsky A, Orkand RK, Kettenmann H. Glial calcium: homeostasis and signaling function. Physiol Rev 1998; 78(1): 99-141.
15. Miyazaki I, Asanuma M, Diaz-Corrales FJ, Miyoshi K, Ogawa N. Direct evidence for expression of dopamine receptors in astrocytes from basal ganglia. Brain Res 2004; 1029(1): 120-3.
16. O'Donnell J, Zeppenfeld D, McConnell E, Pena S, Nedergaard M. Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. Neurochem Res 2012; 37(11): 2496-512.
17. Allaman I, Fiumelli H, Magistretti PJ, Martin JL. Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology (Berl) 2011; 216(1): 75-84.
18. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301(5634): 805-9.
19. Czeh B, Muller-Keuker JI, Rygula R, et al. Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment. Neuropsychopharmacology 2007; 32(7): 1490-503.
20. Araque A, Parpura V, Sanzgiri RP, Haydon PG. Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci 1999; 22(5): 208-15.
21. Araque A, Parpura V, Sanzgiri RP, Haydon PG. Glutamatedependent astrocyte modulation of synaptic transmission between cultured hippocampal neurons. Eur J Neurosci 1998; 10(6): 2129-42.
22. Parpura V, Zorec R. Gliotransmission: Exocytotic release from astrocytes. Brain Res Rev 2010; 63(1-2): 83-92.
23. Zorec R, Araque A, Carmignoto G, Haydon PG, Verkhratsky A, Parpura V. Astroglial excitability and gliotransmission: an appraisal of Ca2+ as a signalling route. ASN Neuro 2012;4(2): pii: e00080.
24. Giaume C, McCarthy KD. Control of gap-junctional communication in astrocytic networks. Trends Neurosci 1996; 19(8): 319-25.
25. Rouach N, Avignone E, Meme W, et al. Gap junctions and connexin expression in the normal and pathological central nervous system. Biol Cell 2002;94(7-8):457-75.
26. Spray DC, Ye ZC, Ransom BR. Functional connexin hemichannels: a critical appraisal. Glia 2006; 54(7): 758-73.
27. Mitterauer BJ. The syncytiopathy hypothesis of depression: downregulation of glial connexins may protract synaptic information processing and cause memory impairment. Med Hypotheses 2010; 74(3): 497-502.
28. Sun JD, Liu Y, Yuan YH, Li J, Chen NH. Gap junction dysfunction in the prefrontal cortex induces depressive-like behaviors in rats. Neuropsychopharmacology 2012; 37(5): 1305-20.
29. Pelton EW, 2nd, Kimelberg HK, Shipherd SV, Bourke RS. Dopamine and norepinephrine uptake and metabolism by astroglial cells in culture. Life Sci 1981; 28(14): 1655-63.
30. Kimelberg HK, Katz DM. Regional differences in 5-hydroxytryptamine and catecholamine uptake in primary astrocyte cultures. J Neurochem 1986; 47(5): 1647-52.
31. Dave V, Kimelberg HK. Na(+)-dependent, fluoxetine-sensitive serotonin uptake by astrocytes tissue-printed from rat cerebral cortex. J Neurosci 1994; 14(8): 4972-86.
32. Hosli E, Hosli L. Autoradiographic studies on the uptake of 3Hnoradrenaline and 3H-serotonin by neurones and astrocytes in explant and primary cultures of rat CNS: effects of antidepressants. Int J Dev Neurosci 1995; 13(8): 897-908.
33. Bal N, Figueras G, Vilaro MT, Sunol C, Artigas F. Antidepressant drugs inhibit a glial 5-hydroxytryptamine transporter in rat brain. Eur J Neurosci 1997; 9(8): 1728-38.
34. Hirst WD, Price GW, Rattray M, Wilkin GP. Serotonin transporters in adult rat brain astrocytes revealed by [3H]5-HT uptake into glial plasmalemmal vesicles. Neurochem Int 1998; 33(1): 11-22.
35. Kittel-Schneider S, Kenis G, Schek J, et al. Expression of monoamine transporters, nitric oxide synthase 3, and neurotrophin genes in antidepressant-stimulated astrocytes. Front Psychiatry 2012; 3: 33.
36. Pickel VM, Chan J. Ultrastructural localization of the serotonin transporter in limbic and motor compartments of the nucleus accumbens. J Neurosci 1999; 19(17): 7356-66.
37. Benmansour S, Cecchi M, Morilak DA, et al. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 1999; 19(23): 10494-501.
38. Horschitz S, Hummerich R, Schloss P. Down-regulation of the rat serotonin transporter upon exposure to a selective serotonin reuptake inhibitor. Neuroreport 2001; 12(10): 2181-4.
39. Hirano K, Seki T, Sakai N, et al. Effects of continuous administration of paroxetine on ligand binding site and expression of serotonin transporter protein in mouse brain. Brain Res 2005; 1053(1-2): 154-61.
40. Semenoff D, Kimelberg HK. Autoradiography of high affinity uptake of catecholamines by primary astrocyte cultures. Brain Res 1985; 348(1): 125-36.
41. Inazu M, Takeda H, Matsumiya T. Functional expression of the norepinephrine transporter in cultured rat astrocytes. J Neurochem 2003; 84(1): 136-44.
42. Hansson E. Transport of monoamine and amino acid neurotransmitters by primary astroglial cultures. Neurochem Res 1985; 10(5): 667-75.
43. Paterson IA, Hertz L. Sodium-independent transport of noradrenaline in mouse and rat astrocytes in primary culture. J Neurosci Res 1989; 23(1): 71-7.
44. Inazu M, Kubota N, Takeda H, et al. Pharmacological characterization of dopamine transport in cultured rat astrocytes. Life Sci 1999; 64(24): 2239-45.
45. Takeda H, Inazu M, Matsumiya T. Astroglial dopamine transport is mediated by norepinephrine transporter. Naunyn Schmiedebergs Arch Pharmacol 2002; 366(6): 620-3.
46. Karakaya S, Kipp M, Beyer C. Oestrogen regulates the expression and function of dopamine transporters in astrocytes of the nigrostriatal system. J Neuroendocrinol 2007; 19(9): 682-90.
47. Hansson E. Enzyme activities of monoamine oxidase, catechol-Omethyltransferase and gamma-aminobutyric acid transaminase in primary astroglial cultures and adult rat brain from different brain regions. Neurochem Res 1984; 9(1): 45-57.
48. Hosli E, Hosli L. Autoradiographic studies on the uptake of 3Hdopamine by neurons and astrocytes in explant and primary cultures of rat CNS: effects of uptake inhibitors. Int J Dev Neurosci 1997; 15(1): 45-53.
49. Inazu M, Takeda H, Ikoshi H, et al. Regulation of dopamine uptake by basic fibroblast growth factor and epidermal growth factor in cultured rat astrocytes. Neurosci Res 1999; 34(4): 235-44.
50. Schomig E, Russ H, Staudt K, Martel F, Gliese M, Grundemann D. The extraneuronal monoamine transporter exists in human central nervous system glia. Adv Pharmacol 1998;42:356-9.
51. Grundemann D, Schechinger B, Rappold GA, Schomig E. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci 1998; 1(5): 349-51.
52. Baganz N, Horton R, Martin K, Holmes A, Daws LC. Repeated swim impairs serotonin clearance via a corticosterone-sensitive mechanism: organic cation transporter 3, the smoking gun. J Neurosci 2010; 30(45): 15185-95.
53. Wu X, Kekuda R, Huang W, et al. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem 1998; 273(49): 32776-86.
54. Wu X, Huang W, Ganapathy ME, et al. Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol 2000; 279(3): F449-58.
55. Kekuda R, Torres-Zamorano V, Leibach FH, Ganapathy V. Human serotonin transporter: regulation by the neuroprotective agent aurintricarboxylic acid and by epidermal growth factor. J Neurochem 1997; 68(4): 1443-50.
56. Eisenhofer G, McCarty R, Pacak K, Russ H, Schomig E. Disprocynium24, a novel inhibitor of the extraneuronal monoamine transporter, has potent effects on the inactivation of circulating noradrenaline and adrenaline in conscious rat. Naunyn Schmiedebergs Arch Pharmacol 1996; 354(3): 287-94.
57. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E. Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol 1999; 56(1): 1-10.
58. Cui M, Aras R, Christian WV, et al. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci USA 2009; 106(19): 8043-8.
59. Gasser PJ, Orchinik M, Raju I, Lowry CA. Distribution of organic cation transporter 3, a corticosterone-sensitive monoamine transporter, in the rat brain. J Comp Neurol 2009; 512(4): 529-55.
60. Vialou V, Amphoux A, Zwart R, Giros B, Gautron S. Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci 2004; 24(11): 2846-51.
61. Fitzgerald LW, Kaplinsky L, Kimelberg HK. Serotonin metabolism by monoamine oxidase in rat primary astrocyte cultures. J Neurochem 1990; 55(6): 2008-14.
62. Squires RF. [Discovery of monoamine oxidase forms A and B]. Vopr Med Khim 1997; 43(6): 433-9.
63. Kaplan GP, Hartman BK, Creveling CR. Immunohistochemical demonstration of catechol-o-methyltransferase in mammalian brain. Brain Res 1979; 167(2): 241-50.
64. Rivett AJ, Francis A, Roth JA. Localization of membrane-bound catechol-O-methyltransferase. J Neurochem 1983; 40(5): 1494-6.
65. Rivett AJ, Francis A, Roth JA. Distinct cellular localization of membrane-bound and soluble forms of catechol-Omethyltransferase in brain. J Neurochem 1983; 40(1): 215-9.
66. Karhunen T, Tilgmann C, Ulmanen I, Panula P. Catechol-Omethyltransferase (COMT) in rat brain: immunoelectron microscopic study with an antiserum against rat recombinant COMT protein. Neurosci Lett 1995; 187(1): 57-60.
67. Azmitia EC, Gannon PJ, Kheck NM, Whitaker-Azmitia PM. Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology 1996; 14(1): 35-46.
68. Whitaker-Azmitia PM, Murphy R, Azmitia EC. Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology. Brain Res 1990; 528(1): 155-8.
69. Eriksen JL, Gillespie R, Druse MJ. Effects of ethanol and 5-HT1A agonists on astroglial S100B. Brain Res Dev Brain Res 2002; 139(2): 97-105.
70. Ramos AJ, Rubio MD, Defagot C, Hischberg L, Villar MJ, Brusco A. The 5HT1A receptor agonist, 8-OH-DPAT, protects neurons and reduces astroglial reaction after ischemic damage caused by cortical devascularization. Brain Res 2004; 1030(2): 201-20.
71. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull 1995; 37(4): 417-29.
72. Ahlemeyer B, Beier H, Semkova I, Schaper C, Krieglstein J. S-100beta protects cultured neurons against glutamate-and staurosporine-induced damage and is involved in the antiapoptotic action of the 5 HT(1A)-receptor agonist, Bay x 3702. Brain Res 2000; 858(1): 121-8.
73. Eriksen JL, Druse MJ. Potential involvement of S100B in the protective effects of a serotonin-1a agonist on ethanol-treated astrocytes. Brain Res Dev Brain Res 2001; 128(2): 157-64.
74. Schroeter ML, Sacher J, Steiner J, Schoenknecht P, Mueller K. Serum S100B Represents a New Biomarker for Mood Disorders. Curr Drug Targets 2013; 14(11): 00-00.
75. Hansson E, Simonsson P, Alling C. 5-Hydroxytryptamine stimulates the formation of inositol phosphate in astrocytes from different regions of the brain. Neuropharmacology 1987; 26(9): 1377-82.
76. Zhang S, Li B, Lovatt D, et al. 5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional 'serotonin-specific reuptake inhibitors'. Neuron Glia Biol 2010; 6(2): 113-25.
77. Meller R, Babity JM, Grahame-Smith DG. 5-HT2A receptor activation leads to increased BDNF mRNA expression in C6 glioma cells. Neuromolecular Med 2002; 1(3): 197-205.
78. Qi X, Lin W, Li J, Pan Y, Wang W. The depressive-like behaviors are correlated with decreased phosphorylation of mitogen-activated protein kinases in rat brain following chronic forced swim stress. Behav Brain Res 2006; 175(2): 233-40.
79. Li B, Zhang S, Li M, Hertz L, Peng L. Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced, transactivation-mediated ERK1/2 phosphorylation. Psychopharmacology (Berl) 2009; 207(1): 1-12.
80. Gourley SL, Wu FJ, Kiraly DD, et al. Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. Biol Psychiatry 2008; 63(4): 353-9.
81. Yuan P, Zhou R, Wang Y, et al. Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. J Affect Disord 2010; 124(1-2): 164-9.
82. Satoh Y, Kobayashi Y, Takeuchi A, Pages G, Pouyssegur J, Kazama T. Deletion of ERK1 and ERK2 in the CNS causes cortical abnormalities and neonatal lethality: Erk1 deficiency enhances the impairment of neurogenesis in Erk2-deficient mice. J Neurosci 2011; 31(3): 1149-55.
83. Peng L, Li B, Du T, et al. Astrocytic transactivation by alpha2Aadrenergic and 5-HT2B serotonergic signaling. Neurochem Int 2010; 57(4): 421-31.
84. Tsuchioka M, Takebayashi M, Hisaoka K, Maeda N, Nakata Y. Serotonin (5-HT) induces glial cell line-derived neurotrophic factor (GDNF) mRNA expression via the transactivation of fibroblast growth factor receptor 2 (FGFR2) in rat C6 glioma cells. J Neurochem 2008; 106(1): 244-57.
85. Tsuchioka M, Hisaoka K, Yano R, Shibasaki C, Kajiatani N, Takebayashi M. Riluzole-induced glial cell line-derived neurotrophic factor production is regulated through fibroblast growth factor receptor signaling in rat C6 glioma cells. Brain Res 2011; 1384: 1-8.
86. Parga J, Rodriguez-Pallares J, Munoz A, Guerra MJ, Labandeira-Garcia JL. Serotonin decreases generation of dopaminergic neurons from mesencephalic precursors via serotonin type 7 and type 4 receptors. Dev Neurobiol 2007; 67(1): 10-22.
87. Carson MJ, Thomas EA, Danielson PE, Sutcliffe JG. The 5HT5A serotonin receptor is expressed predominantly by astrocytes in which it inhibits cAMP accumulation: a mechanism for neuronal suppression of reactive astrocytes. Glia 1996; 17(4): 317-26.
88. Shen Y, Monsma FJ, Jr., Metcalf MA, Jose PA, Hamblin MW, Sibley DR. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem 1993; 268(24): 18200-4.
89. Shimizu M, Nishida A, Zensho H, Yamawaki S. Chronic antidepressant exposure enhances 5-hydroxytryptamine7 receptormediated cyclic adenosine monophosphate accumulation in rat frontocortical astrocytes. J Pharmacol Exp Ther 1996; 279(3): 1551-8.
90. Mahe C, Bernhard M, Bobirnac I, et al. Functional expression of the serotonin 5-HT7 receptor in human glioblastoma cell lines. Br J Pharmacol 2004; 143(3): 404-10.
91. Lieb K, Biersack L, Waschbisch A, et al. Serotonin via 5-HT7 receptors activates p38 mitogen-activated protein kinase and protein kinase C epsilon resulting in interleukin-6 synthesis in human U373 MG astrocytoma cells. J Neurochem 2005; 93(3): 549-59.
92. Shao Y, Sutin J. Expression of adrenergic receptors in individual astrocytes and motor neurons isolated from the adult rat brain. Glia 1992; 6(2): 108-17.
93. Aoki C, Venkatesan C, Go CG, Forman R, Kurose H. Cellular and subcellular sites for noradrenergic action in the monkey dorsolateral prefrontal cortex as revealed by the immunocytochemical localization of noradrenergic receptors and axons. Cereb Cortex 1998; 8(3): 269-77.
94. Glass MJ, Huang J, Aicher SA, Milner TA, Pickel VM. Subcellular localization of alpha-2A-adrenergic receptors in the rat medial nucleus tractus solitarius: regional targeting and relationship with catecholamine neurons. J Comp Neurol 2001; 433(2): 193-207.
95. Cahoy JD, Emery B, Kaushal A, et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 2008; 28(1): 264-78.
96. Hertz L, Lovatt D, Goldman SA, Nedergaard M. Adrenoceptors in brain: cellular gene expression and effects on astrocytic metabolism and [Ca(2+)]i. Neurochem Int 2010; 57(4): 411-20.
97. Hertz L, Chen Y, Gibbs ME, Zang P, Peng L. Astrocytic adrenoceptors: a major drug target in neurological and psychiatric disorders? Curr Drug Targets CNS Neurol Disord 2004; 3(3): 239-67.
98. Bekar LK, He W, Nedergaard M. Locus coeruleus alphaadrenergic-mediated activation of cortical astrocytes in vivo. Cereb Cortex 2008; 18(12): 2789-95.
99. Juric DM, Loncar D, Carman-Krzan M. Noradrenergic stimulation of BDNF synthesis in astrocytes: mediation via alpha1-and beta1/beta2-adrenergic receptors. Neurochem Int 2008; 52(1-2): 297-306.
100. Miklic S, Juric DM, Carman-Krzan M. Differences in the regulation of BDNF and NGF synthesis in cultured neonatal rat astrocytes. Int J Dev Neurosci 2004; 22(3): 119-30.
101. Conner JM, Lauterborn JC, Yan Q, Gall CM, Varon S. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J Neurosci 1997; 17(7): 2295-313.
102. Yan Q, Radeke MJ, Matheson CR, Talvenheimo J, Welcher AA, Feinstein SC. Immunocytochemical localization of TrkB in the central nervous system of the adult rat. J Comp Neurol 1997; 378(1): 135-57.
103. Subbarao KV, Hertz L. Stimulation of energy metabolism by alpha-adrenergic agonists in primary cultures of astrocytes. J Neurosci Res 1991; 28(3): 399-405.
104. Pellerin L, Stolz M, Sorg O, Martin JL, Deschepper CF, Magistretti PJ. Regulation of energy metabolism by neurotransmitters in astrocytes in primary culture and in an immortalized cell line. Glia 1997; 21(1): 74-83.
105. Werry TD, Wilkinson GF, Willars GB. Mechanisms of cross-talk between G-protein-coupled receptors resulting in enhanced release of intracellular Ca2+. Biochem J 2003; 374(Pt 2): 281-96.
106. Magistretti PJ, Sorg O, Yu N, Martin JL, Pellerin L. Neurotransmitters regulate energy metabolism in astrocytes: implications for the metabolic trafficking between neural cells. Dev Neurosci 1993; 15(3-5): 306-12.
107. Brown AM. Brain glycogen re-awakened. J Neurochem 2004; 89(3): 537-52.
108. Dienel GA, Ball KK, Cruz NF. A glycogen phosphorylase inhibitor selectively enhances local rates of glucose utilization in brain during sensory stimulation of conscious rats: implications for glycogen turnover. J Neurochem 2007; 102(2): 466-78.
109. Belanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 2011; 14(6): 724-38.
110. Summers RJ, Papaioannou M, Harris S, Evans BA. Expression of beta 3-adrenoceptor mRNA in rat brain. Br J Pharmacol 1995; 116(6): 2547-8.
111. Junker V, Becker A, Huhne R, et al. Stimulation of betaadrenoceptors activates astrocytes and provides neuroprotection. Eur J Pharmacol 2002; 446(1-3): 25-36.
112. Ghosh M, Das S. Increased beta(2)-adrenergic receptor activity by thyroid hormone possibly leads to differentiation and maturation of astrocytes in culture. Cell Mol Neurobiol 2007; 27(8): 1007-21.
113. Catus SL, Gibbs ME, Sato M, Summers RJ, Hutchinson DS. Role of beta-adrenoceptors in glucose uptake in astrocytes using betaadrenoceptor knockout mice. Br J Pharmacol 2011; 162(8): 1700-15.
114. Daaka Y, Pitcher JA, Richardson M, Stoffel RH, Robishaw JD, Lefkowitz RJ. Receptor and G betagamma isoform-specific interactions with G protein-coupled receptor kinases. Proc Natl Acad Sci USA 1997; 94(6): 2180-5.
115. Sato M, Hutchinson DS, Bengtsson T, et al. Functional domains of the mouse beta3-adrenoceptor associated with differential G protein coupling. J Pharmacol Exp Ther 2005; 315(3): 1354-61.
116. Hutchinson DS, Summers RJ, Gibbs ME. Beta2-and beta3-adrenoceptors activate glucose uptake in chick astrocytes by distinct mechanisms: a mechanism for memory enhancement? J Neurochem 2007; 103(3): 997-1008.
117. Sato M, Hutchinson DS, Evans BA, Summers RJ. Functional domains of the mouse beta(3)-adrenoceptor associated with differential G-protein coupling. Biochem Soc Trans 2007; 35(Pt 5): 1035-7.
118. Sorg O, Magistretti PJ. Characterization of the glycogenolysis elicited by vasoactive intestinal peptide, noradrenaline and adenosine in primary cultures of mouse cerebral cortical astrocytes. Brain Res 1991; 563(1-2): 227-33.
119. O'Dowd BS, Barrington J, Ng KT, Hertz E, Hertz L. Glycogenolytic response of primary chick and mouse cultures of astrocytes to noradrenaline across development. Brain Res Dev Brain Res 1995; 88(2): 220-3.
120. Juric DM, Miklic S, Carman-Krzan M. Monoaminergic neuronal activity up-regulates BDNF synthesis in cultured neonatal rat astrocytes. Brain Res 2006; 1108(1): 54-62.
121. Chen MJ, Nguyen TV, Pike CJ, Russo-Neustadt AA. Norepinephrine induces BDNF and activates the PI-3K and MAPK cascades in embryonic hippocampal neurons. Cell Signal 2007; 19(1): 114-28.
122. Sklair-Tavron L, Nestler EJ. Opposing effects of morphine and the neurotrophins, NT-3, NT-4, and BDNF, on locus coeruleus neurons in vitro. Brain Res 1995; 702(1-2): 117-25.
123. Russo-Neustadt AA, Chen MJ. Brain-derived neurotrophic factor and antidepressant activity. Curr Pharm Des 2005; 11(12): 1495-510.
124. Carter CJ. Multiple genes and factors associated with bipolar disorder converge on growth factor and stress activated kinase pathways controlling translation initiation: implications for oligodendrocyte viability. Neurochem Int 2007; 50(3): 461-90.
125. Somjen GG, Kager H, Wadman WJ. Computer simulations of neuron-glia interactions mediated by ion flux. J Comput Neurosci 2008; 25(2): 349-65.
126. Hajek I, Subbarao KV, Hertz L. Acute and chronic effects of potassium and noradrenaline on Na+, K+-ATPase activity in cultured mouse neurons and astrocytes. Neurochem Int 1996; 28(3): 335-42.
127. Pesce L, Comellas A, Sznajder JI. Beta-adrenergic agonists regulate Na-K-ATPase via p70S6k. Am J Physiol Lung Cell Mol Physiol 2003; 285(4): L802-7.
128. Bal A, Bachelot T, Savasta M, et al. Evidence for dopamine D2 receptor mRNA expression by striatal astrocytes in culture: in situ hybridization and polymerase chain reaction studies. Brain Res Mol Brain Res 1994; 23(3): 204-12.
129. Zanassi P, Paolillo M, Montecucco A, Avvedimento EV, Schinelli S. Pharmacological and molecular evidence for dopamine D(1) receptor expression by striatal astrocytes in culture. J Neurosci Res 1999; 58(4): 544-52.
130. Inoue S, Susukida M, Ikeda K, Murase K, Hayashi K. Dopaminergic transmitter up-regulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) synthesis in mouse astrocytes in culture. Biochem Biophys Res Commun 1997; 238(2): 468-72.
131. Imamura K, Takeshima T, Nakaso K, Ito S, Nakashima K. Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity. Neurosci Lett 2008; 440(2): 97-102.
132. Ohta M, Mizuta I, Ohta K, et al. Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun 2000; 272(1): 18-22.
133. Ohta K, Kuno S, Inoue S, Ikeda E, Fujinami A, Ohta M. The effect of dopamine agonists: the expression of GDNF, NGF, and BDNF in cultured mouse astrocytes. J Neurol Sci 2010; 291(1-2): 12-6.
134. Li A, Guo H, Luo X, et al. Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons. Faseb J 2006;20(8): 1263-5.
135. Luo X, Zhang X, Shao W, Yin Y, Zhou J. Crucial roles of MZF-1 in the transcriptional regulation of apomorphine-induced modulation of FGF-2 expression in astrocytic cultures. J Neurochem 2009; 108(4): 952-61.
136. Khan ZU, Koulen P, Rubinstein M, Grandy DK, Goldman-Rakic PS. An astroglia-linked dopamine D2-receptor action in prefrontal cortex. Proc Natl Acad Sci USA 2001; 98(4): 1964-9.
137. Guiard BP, David DJ, Deltheil T, et al. Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperserotonergic phenotype. Int J Neuropsychopharmacol 2008; 11(1): 79-92.
138. Prickaerts J, De Vry J, Boere J, et al. Differential BDNF responses of triple versus dual reuptake inhibition in neuronal and astrocytoma cells as well as in rat hippocampus and prefrontal cortex. J Mol Neurosci 2012; 48(1): 167-75.
139. Frail DE, Manelli AM, Witte DG, Lin CW, Steffey ME, Mackenzie RG. Cloning and characterization of a truncated dopamine D1 receptor from goldfish retina: stimulation of cyclic AMP production and calcium mobilization. Mol Pharmacol 1993; 44(6): 1113-8.
140. Jin LQ, Goswami S, Cai G, Zhen X, Friedman E. SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain. J Neurochem 2003; 85(2): 378-86.
141. Zhang X, Zhou Z, Wang D, et al. Activation of phosphatidylinositol-linked D1-like receptor modulates FGF-2 expression in astrocytes via IP3-dependent Ca2+ signaling. J Neurosci 2009; 29(24): 7766-75.
142. Huang C, Wu J, Liao R, Zhang W. SKF83959, an agonist of phosphatidylinositol-linked D(1)-like receptors, promotes ERK1/2 activation and cell migration in cultured rat astrocytes. PLoS One 2012; 7(11): e49954.
143. Martin JL, Magistretti PJ, Allaman I. Regulation of Neurotrophic Factors and Energy Metabolism by Antidepressants in Astrocytes. Curr Drug Targets 2013.
144. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998; 95(22): 13290-5.
145. Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999; 45(9): 1085-98.
146. Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 2002; 12(4): 386-94.
147. Trzeciak HI, Pudelko A, Gabryel B, Malecki A, Kozlowski A, Ciesslik P. Effect of antidepressants on ATP content, 3H-valine incorporation and cell morphometry of astrocytes cultured from rat brain. Dev Neurosci 1995; 17(5-6): 292-9.
148. Cao X, Li LP, Wang Q, et al. Astrocyte-derived ATP modulates depressive-like behaviors. Nat Med 2013.
149. Cao X, Li LP, Qin XH, et al. Astrocytic ATP release regulates the proliferation of neural stem cells in the adult hippocampus. Stem Cells 2013.
150. Kaster MP, Machado DG, Santos AR, Rodrigues AL. Involvement of NMDA receptors in the antidepressant-like action of adenosine. Pharmacol Rep 2012; 64(3): 706-13.
151. Kaster MP, Budni J, Binfare RW, Santos AR, Rodrigues AL. The inhibition of different types of potassium channels underlies the antidepressant-like effect of adenosine in the mouse forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(3): 690-6.
152. Kaster MP, Budni J, Santos AR, Rodrigues AL. Pharmacological evidence for the involvement of the opioid system in the antidepressant-like effect of adenosine in the mouse forced swimming test. Eur J Pharmacol 2007; 576(1-3): 91-8.
153. Kaster MP, Rosa AO, Santos AR, Rodrigues AL. Involvement of nitric oxide-cGMP pathway in the antidepressant-like effects of adenosine in the forced swimming test. Int J Neuropsychopharmacol 2005; 8(4): 601-6.
154. Kaster MP, Rosa AO, Rosso MM, Goulart EC, Santos AR, Rodrigues AL. Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A1 and A2A receptors. Neurosci Lett 2004; 355(1-2): 21-4.
155. Lewin E, Bleck V. Electroshock seizures in mice: effect on brain adenosine and its metabolites. Epilepsia 1981; 22(5): 577-81.
156. van Calker D, Biber K. The role of glial adenosine receptors in neural resilience and the neurobiology of mood disorders. Neurochem Res 2005; 30(10): 1205-17.
157. Hines DJ, Schmitt LI, Hines RM, Moss SJ, Haydon PG. Antidepressant effects of sleep deprivation require astrocyte-dependent adenosine mediated signaling. Transl Psychiatry 2013; 3: e212.
158. Okada M, Kawata Y, Murakami T, et al. Differential effects of adenosine receptor subtypes on release and reuptake of hippocampal serotonin. Eur J Neurosci 1999; 11(1): 1-9.
159. Okada M, Nutt DJ, Murakami T, et al. Adenosine receptor subtypes modulate two major functional pathways for hippocampal serotonin release. J Neurosci 2001; 21(2): 628-40.
160. Diogenes MJ, Fernandes CC, Sebastiao AM, Ribeiro JA. Activation of adenosine A2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J Neurosci 2004; 24(12): 2905-13.
161. Mothet JP, Parent AT, Wolosker H, et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 2000; 97(9): 4926-31.
162. Malkesman O, Austin DR, Tragon T, et al. Acute D-serine treatment produces antidepressant-like effects in rodents. Int J Neuropsychopharmacol 2012; 15(8): 1135-48.
163. Zink M, Rapp S, Donev R, Gebicke-Haerter PJ, Thome J. Fluoxetine treatment induces EAAT2 expression in rat brain. J Neural Transm 2011; 118(6): 849-55.
164. Gourley SL, Espitia JW, Sanacora G, Taylor JR. Antidepressantlike properties of oral riluzole and utility of incentive disengagement models of depression in mice. Psychopharmacology (Berl) 2012; 219(3): 805-14.
165. Choudary PV, Molnar M, Evans SJ, et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 2005; 102(43): 15653-8.
166. Bernard R, Kerman IA, Thompson RC, et al. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol Psychiatry 2011; 16(6): 634-46.
167. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res 1996; 711(1-2): 163-74.
168. Castanon N, Medina C, Mormede C, Dantzer R. Chronic administration of tianeptine balances lipopolysaccharide-induced expression of cytokines in the spleen and hypothalamus of rats. Psychoneuroendocrinology 2004; 29(6): 778-90.
169. Kohman RA, Rhodes JS. Neurogenesis, inflammation and behavior. Brain Behav Immun 2012; 27(1): 22-32.
170. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003; 302(5651): 1760-5.
171. O'Sullivan JB, Ryan KM, Curtin NM, Harkin A, Connor TJ. Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. Int J Neuropsychopharmacol 2009; 12(5): 687-99.
172. Hwang J, Zheng LT, Ock J, et al. Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology 2008; 55(5): 826-34.
173. Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci USA 2003; 100(23): 13632-7.
174. Liu D, Wang Z, Liu S, Wang F, Zhao S, Hao A. Anti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells. Neuropharmacology 2011; 61(4): 592-9.
175. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000; 22(4): 370-9.
176. Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR. Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(5): 899-905.
177. Pitychoutis PM, Nakamura K, Tsonis PA, Papadopoulou-Daifoti Z. Neurochemical and behavioral alterations in an inflammatory model of depression: sex differences exposed. Neuroscience 2009; 159(4): 1216-32.
178. Leonard BE, Song C. Changes in the immune system in rodent models of depression. Int J Neuropsychopharmacol 2002; 5(4): 345-56.
179. Hashioka S. Antidepressants and neuroinflammation: Can antidepressants calm glial rage down? Mini Rev Med Chem 2011; 11(7): 555-64.
180. Makar TK, Bever CT, Singh IS, et al. Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J Neuroimmunol 2009; 210(1-2): 40-51.
181. Sierra A, Encinas JM, Deudero JJ, et al. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. Cell Stem Cell 2010; 7(4): 483-95.
182. Di Benedetto B, Rupprecht R, Czeh B. Talking to the synapse: how antidepressants can target glial cells to reshape brain circuits. Curr Drug Targets 2013.
183. Czeh B, Fuchs E, Flugge G. Altered Glial Plasticity in Animal Models For Mood Disorders. Curr Drug Targets 2013.
184. Kyritsis N, Kizil C, Zocher S, et al. Acute inflammation initiates the regenerative response in the adult zebrafish brain. Science 2012; 338(6112): 1353-6.
185. Tramontina AC, Tramontina F, Bobermin LD, et al. Secretion of S100B, an astrocyte-derived neurotrophic protein, is stimulated by fluoxetine via a mechanism independent of serotonin. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(6): 1580-3.
186. Rong H, Wang G, Liu T, Wang H, Wan Q, Weng S. Chronic Mild Stress Induces Fluoxetine-Reversible Decreases in Hippocampal and Cerebrospinal Fluid Levels of the Neurotrophic Factor S100B and Its Specific Receptor. Int J Mol Sci 2010; 11(12): 5310-22.
187. Akhisaroglu M, Manev R, Akhisaroglu E, Uz T, Manev H. Both aging and chronic fluoxetine increase S100B content in the mouse hippocampus. Neuroreport 2003; 14(11): 1471-3.
188. Kleindienst A, McGinn MJ, Harvey HB, Colello RJ, Hamm RJ, Bullock MR. Enhanced hippocampal neurogenesis by intraventricular S100B infusion is associated with improved cognitive recovery after traumatic brain injury. J Neurotrauma 2005; 22(6): 645-55.
189. Arolt V, Peters M, Erfurth A, et al. S100B and response to treatment in major depression: a pilot study. Eur Neuropsychopharmacol 2003; 13(4): 235-9.
190. Jang BS, Kim H, Lim SW, Jang KW, Kim DK. Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response. Psychiatry Investig 2008; 5(3): 193-8.
191. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O. miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 2010; 329(5998): 1537-41.
192. Quesseveur G, Nguyen HT, Gardier AM, Guiard BP. 5-HT2 ligands in the treatment of anxiety and depression. Expert Opin Investig Drugs 2012; 21(11): 1701-25.
193. Quesseveur G, Reperant C, David DJ, Gardier AM, Sanchez C, Guiard BP. 5-HT(2)A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system. Exp Brain Res 2013; 226(2): 285-95.
194. Paratcha G, Ledda F. GDNF and GFRalpha: a versatile molecular complex for developing neurons. Trends Neurosci 2008; 31(8): 384-91.
195. Henderson CE, Phillips HS, Pollock RA, et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 1994; 266(5187): 1062-4.
196. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002; 3(5): 383-94.
197. Uchida S, Hara K, Kobayashi A, et al. Epigenetic status of Gdnf in the ventral striatum determines susceptibility and adaptation to daily stressful events. Neuron 2011; 69(2): 359-72.
198. Liu Q, Zhu HY, Li B, Wang YQ, Yu J, Wu GC. Chronic clomipramine treatment restores hippocampal expression of glial cell line-derived neurotrophic factor in a rat model of depression. J Affect Disord 2012; 141(2-3): 367-72.
199. Kajitani N, Hisaoka-Nakashima K, Morioka N, et al. Antidepressant acts on astrocytes leading to an increase in the expression of neurotrophic/growth factors: differential regulation of FGF-2 by noradrenaline. PLoS One 2012; 7(12): e51197.
200. Hisaoka K, Takebayashi M, Tsuchioka M, Maeda N, Nakata Y, Yamawaki S. Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine-independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells. J Pharmacol Exp Ther 2007; 321(1): 148-57.
201. Mercier G, Lennon AM, Renouf B, et al. MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. J Mol Neurosci 2004; 24(2): 207-16.
202. Wada T, Haigh JJ, Ema M, et al. Vascular endothelial growth factor directly inhibits primitive neural stem cell survival but promotes definitive neural stem cell survival. J Neurosci 2006; 26(25): 6803-12.
203. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 2002; 99(18): 11946-50.
204. Fournier NM, Duman RS. Role of vascular endothelial growth factor in adult hippocampal neurogenesis: implications for the pathophysiology and treatment of depression. Behav Brain Res 2012; 227(2): 440-9.
205. Licht T, Goshen I, Avital A, et al. Reversible modulations of neuronal plasticity by VEGF. Proc Natl Acad Sci USA 2011; 108(12): 5081-6.
206. Warner-Schmidt JL, Duman RS. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA 2007; 104(11): 4647-52.
207. Warner-Schmidt JL, Duman RS. VEGF as a potential target for therapeutic intervention in depression. Curr Opin Pharmacol 2008; 8(1): 14-9.
208. Greene J, Banasr M, Lee B, Warner-Schmidt J, Duman RS. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 2009; 34(11): 2459-68.
209. Krum JM, Mani N, Rosenstein JM. Angiogenic and astroglial responses to vascular endothelial growth factor administration in adult rat brain. Neuroscience 2002; 110(4): 589-604.
210. Gaughran F, Payne J, Sedgwick PM, Cotter D, Berry M. Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Res Bull 2006; 70(3): 221-7.
211. Evans SJ, Choudary PV, Neal CR, et al. Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci USA 2004; 101(43): 15506-11.
212. Turner CA, Gula EL, Taylor LP, Watson SJ, Akil H. Antidepressant-like effects of intracerebroventricular FGF2 in rats. Brain Res 2008; 1224: 63-8.
213. Bachis A, Mallei A, Cruz MI, Wellstein A, Mocchetti I. Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons. Neuropharmacology 2008; 55(7): 1114-20.
214. Mallei A, Shi B, Mocchetti I. Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal neurons. Mol Pharmacol 2002; 61(5): 1017-24.
215. Elsayed M, Banasr M, Duric V, Fournier NM, Licznerski P, Duman RS. Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression. Biol Psychiatry 2012; 72(4): 258-65.
216. Samuels BA, Hen R. Neurogenesis and affective disorders. Eur J Neurosci 2011; 33(6): 1152-9.
217. Zetterstrom TS, Pei Q, Madhav TR, Coppell AL, Lewis L, Grahame-Smith DG. Manipulations of brain 5-HT levels affect gene expression for BDNF in rat brain. Neuropharmacology 1999; 38(7): 1063-73.
218. Coppell AL, Pei Q, Zetterstrom TS. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 2003; 44(7): 903-10.
219. Dias BG, Banerjee SB, Duman RS, Vaidya VA. Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain. Neuropharmacology 2003; 45(4): 553-63.
220. De Foubert G, Carney SL, Robinson CS, et al. Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience 2004; 128(3): 597-604.
221. Khundakar AA, Zetterstrom TSC. Differential expression of BDNF exons in rat brain after systemic administration of paroxetine and tranylcypromine. British Journal of Pharmacology 2002; 137.
222. Khundakar AA, Zetterstrom TSC. Biphasic change in BDNF gene expression following antidepressant drug treatment explained by differential transcript regulation. Brain Research 2006; 1106: 12-20.
223. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15(11): 7539-47.
224. Duman RS, Monteggia LM. A neurotrophic model for stressrelated mood disorders. Biol Psychiatry 2006; 59(12): 1116-27.
225. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. Journal of Neuroscience 1996; 16(7): 2365-2372.
226. Duman RS. Novel therapeutic approaches beyond the serotonin receptor. Biological Psychiatry 1998; 44(5): 324-335.
227. Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME. Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 1998; 20(4): 709-26.
228. Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA. cAMP response element-binding protein is essential for the upregulation of brainderived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 2002; 22(8): 3262-8.
229. Ghosh A, Carnahan J, Greenberg ME. Requirement for BDNF in activity-dependent survival of cortical neurons. Science 1994; 263(5153): 1618-23.
230. Carriba P, Pardo L, Parra-Damas A, et al. ATP and noradrenaline activate CREB in astrocytes via noncanonical Ca(2+) and cyclic AMP independent pathways. Glia 2012; 60(9): 1330-44.
231. Takano K, Yamasaki H, Kawabe K, Moriyama M, Nakamura Y. Imipramine induces brain-derived neurotrophic factor mRNA expression in cultured astrocytes. J Pharmacol Sci 2012; 120(3): 176-86.
232. Deltheil T, Tanaka K, Reperant C, Hen R, David DJ, Gardier AM. Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and an tidepressants in adult mice. Int J Neuropsychopharmacol 2009; 12(7): 905-15.
233. Hoshaw BA, Malberg JE, Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 2005; 1037(1-2): 204-8.
234. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22(8): 3251-61.
235. Siuciak JA, Boylan C, Fritsche M, Altar CA, Lindsay RM. BDNF increases monoaminergic activity in rat brain following intracerebroventricular or intraparenchymal administration. Brain Res 1996; 710(1-2): 11-20.
236. Rantamaki T, Vesa L, Antila H, et al. Antidepressant drugs transactivate TrkB neurotrophin receptors in the adult rodent brain independently of BDNF and monoamine transporter blockade. PLoS One 2011; 6(6): e20567.
237. Rantamaki T, Knuuttila JE, Hokkanen ME, Castren E. The effects of acute and long-term lithium treatments on trkB neurotrophin receptor activation in the mouse hippocampus and anterior cingulate cortex. Neuropharmacology 2006; 50(4): 421-7.
238. Saarelainen T, Hendolin P, Lucas G, et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003; 23(1): 349-57.
239. Ibarguen-Vargas Y, Surget A, Vourc'h P, et al. Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress. Behav Brain Res 2009; 202(2): 245-51.
240. Taliaz D, Stall N, Dar DE, Zangen A. Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Mol Psychiatry 2010; 15(1): 80-92.
241. Li Y, Luikart BW, Birnbaum S, et al. TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron 2008; 59(3): 399-412.
242. Sairanen M, Lucas G, Ernfors P, Castren M, Castren E. Brainderived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J Neurosci 2005; 25(5): 1089-94.
243. Lee J, Duan W, Mattson MP. Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J Neurochem 2002; 82(6): 1367-75.
244. Wang SH, Zhang ZJ, Guo YJ, Teng GJ, Chen BA. Hippocampal neurogenesis and behavioural studies on adult ischemic rat response to chronic mild stress. Behav Brain Res 2008; 189(1): 9-16.
245. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50(4): 260-5.
246. Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci USA 1995; 92(19):8856-60.
247. Giralt A, Friedman HC, Caneda-Ferron B, et al. BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease. Gene Ther 2010; 17(10): 1294-308.
248. Rudge JS, Pasnikowski EM, Holst P, Lindsay RM. Changes in neurotrophic factor expression and receptor activation following exposure of hippocampal neuron/astrocyte cocultures to kainic acid. J Neurosci 1995; 15(10): 6856-67.
249. Dieni S, Matsumoto T, Dekkers M, et al. BDNF and its pro-peptide are stored in presynaptic dense core vesicles in brain neurons. J Cell Biol 2012; 196(6): 775-88.
250. Colin A, Faideau M, Dufour N, et al. Engineered lentiviral vector targeting astrocytes in vivo. Glia 2009; 57(6): 667-79.
251. Quesseveur G, David DJ, Gaillard MC, et al. BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities. Transl Psychiatry 2013; 3: e253.
252. Mamounas LA, Altar CA, Blue ME, Kaplan DR, Tessarollo L, Lyons WE. BDNF promotes the regenerative sprouting, but not survival, of injured serotonergic axons in the adult rat brain. J Neurosci 2000; 20(2): 771-82.
253. Ivanova T, Beyer C. Pre-and postnatal expression of brain-derived neurotrophic factor mRNA/protein and tyrosine protein kinase receptor B mRNA in the mouse hippocampus. Neurosci Lett 2001; 307(1): 21-4.
254. Ohira K, Kumanogoh H, Sahara Y, et al. A truncated tropomyosinrelated kinase B receptor, T1, regulates glial cell morphology via Rho GDP dissociation inhibitor 1. J Neurosci 2005; 25(6): 1343-53.
255. Dougherty KD, Milner TA. p75NTR immunoreactivity in the rat dentate gyrus is mostly within presynaptic profiles but is also found in some astrocytic and postsynaptic profiles. J Comp Neurol 1999; 407(1): 77-91.
256. Cragnolini AB, Huang Y, Gokina P, Friedman WJ. Nerve growth factor attenuates proliferation of astrocytes via the p75 neurotrophin receptor. Glia 2009; 57(13): 1386-92.
257. Guo J, Wang J, Zhang Z, et al. proNGF Inhibits Neurogenesis and Induces Glial Activation in Adult Mouse Dentate Gyrus. Neurochem Res 2013; 38(8): 1695-703.
258. Bergami M, Santi S, Formaggio E, et al. Uptake and recycling of pro-BDNF for transmitter-induced secretion by cortical astrocytes. J Cell Biol 2008; 183(2): 213-21.
259. Bruzzone R, White TW, Paul DL. Connections with connexins: the molecular basis of direct intercellular signaling. Eur J Biochem 1996; 238(1): 1-27.
260. Orellana JA, Saez PJ, Shoji KF, et al. Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegeneration. Antioxid Redox Signal 2009; 11(2): 369-99.
261. Figueiredo M, Lane S, Tang F, et al. Optogenetic experimentation on astrocytes. Exp Physiol 2011; 96(1): 40-50.
262. Han X, Chen M, Wang F, et al. Forebrain engraftment by human glial progenitor cells enhances synaptic plasticity and learning in adult mice. Cell Stem Cell 2013; 12(3): 342-53.
263. Deecher DC, Wilcox BD, Dave V, Rossman PA, Kimelberg HK. Detection of 5-hydroxytryptamine2 receptors by radioligand binding, northern blot analysis, and Ca2+ responses in rat primary astrocyte cultures. J Neurosci Res 1993; 35(3): 246-56.
264. Kong EK, Peng L, Chen Y, Yu AC, Hertz L. Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. Neurochem Res 2002; 27(1-2): 113-20.
265. Zeinstra EM, Wilczak N, Wilschut JC, et al. 5HT4 agonists inhibit interferon-gamma-induced MHC class II and B7 costimulatory molecules expression on cultured astrocytes. J Neuroimmunol 2006; 179(1-2): 191-5.
266. Lin R, Karpa K, Kabbani N, Goldman-Rakic P, Levenson R. Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A. Proc Natl Acad Sci USA 2001; 98(9): 5258-63.
267. Duffy AM, Fitzgerald ML, Chan J, et al. Acetylcholine alpha7 nicotinic and dopamine D2 receptors are targeted to many of the same postsynaptic dendrites and astrocytes in the rodent prefrontal cortex. Synapse 2011; 65(12): 1350-67.